An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease-Reference-Cited by-同舟云学术

An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease

Published:2020-12-11 Issue:50 Volume:99 Page:e23291
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Koga Tomohiro,Takemori Sachiko,Hagimori Naoko,Morimoto Shimpei,Sumiyoshi Remi,Shimizu Toshimasa,Hosogaya Naoki,Fukushima Chizu,Yamamoto Hiroshi,Kawakami Atsushi

Funder

Japan Agency for Medical Research and Development

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference16 articles.

1. Localized mediastinal lymphnode hyperplasia resembling thymoma;Castleman;Cancer,1956

2. Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course;Bartoli;Am J Clin Pathol,1980

3. The clinical behavior of localized and multicentric Castleman disease;Herrada;Ann Intern Med,1998

4. Castleman's disease: systematic analysis of 416 patients from the literature;Talat;Oncologist,2011

5. Clinical features and treatment of multicentric Castleman's disease: a retrospective study of 21 Japanese patients at a single institute;Kawabata;J Clin Exp Hematop,2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunology and targeted therapy in Castleman disease;Expert Review of Clinical Immunology;2024-05-27

2. How We Manage Idiopathic Multicentric Castleman Disease;CLIN ADV HEMATOL ONC;2022

3. A case of tocilizumab-refractory idiopathic multicentric Castleman's disease successfully treated with sirolimus;Clinical Immunology;2021-12